Form 4: Supernus Pharmaceuticals Director Carrolee Barlow Reports Stock Transactions

Director Carrolee Barlow of Supernus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units on February 22, 2025.

Summary

• On February 22, 2025, Carrolee Barlow, a director of Supernus Pharmaceuticals, engaged in transactions involving the company's stock.
• Barlow acquired 5,369 shares of common stock.
• Simultaneously, Barlow disposed of 5,369 restricted stock units, which were settled in common stock upon vesting on the same date.
• Following these transactions, Barlow directly owns 22,570 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is a common occurrence in publicly traded companies. It provides transparency into the trading activities of individuals with access to inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly altering the ownership structure of the company.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Transactions, Form 4, Beneficial Ownership, Carrolee Barlow, SUPN, Restricted Stock Units, Common Stock